- Trials with a EudraCT protocol (111)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
111 result(s) found for: Bloating.
Displaying page 3 of 6.
EudraCT Number: 2022-004155-13 | Sponsor Protocol Number: BMS_IM101-931 | Start Date*: 2023-04-20 | |||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||
Full Title: Study to investigate the restoring of an immunological balance during therapy with abatacept Abatacept restores immune system equilibrium (ARISE) | |||||||||||||
Medical condition: CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positiv... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004400-35 | Sponsor Protocol Number: 2016/1529 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: The ReSScue trial. Aiming to Reduce disease-related gastro-intestinal symptoms in patients with Systemic Sclerosis by repeat intestinal infusions of Anaerobic Cultivated Human Intestinal Microbiome... | |||||||||||||
Medical condition: Systemic sclerosis (SSc) is a rare, complex, multi-organ disorder characterized by immune-mediated inflammation, progressive organ fibrosis and vascular pathology leading to small vessel obliterati... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001309-60 | Sponsor Protocol Number: MK4280A-007 | Start Date*: 2021-10-08 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer | |||||||||||||
Medical condition: Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Completed) CZ (Completed) NO (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022991-29 | Sponsor Protocol Number: SMR/0211OBD-1033 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:Sucampo Pharma Americas, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction | |||||||||||||
Medical condition: Opioid-induced Bowel Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001912-31 | Sponsor Protocol Number: BUG-3/MIC | Start Date*: 2014-02-19 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis | |||||||||||||
Medical condition: Patients with active incomplete microscopic colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) ES (Completed) SE (Completed) NL (Prematurely Ended) DK (Completed) LT (Completed) PT (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002254-86 | Sponsor Protocol Number: NAT-19/GPX | Start Date*: 2022-09-26 | ||||||||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | ||||||||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at l... | ||||||||||||||||||
Medical condition: idiopathic or diabetic gastroparesis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001601-24 | Sponsor Protocol Number: 27018966IBS3002 | Start Date*: 2012-08-13 | ||||||||||||||||
Sponsor Name:Furiex Pharmaceuticals | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow... | ||||||||||||||||||
Medical condition: Diarrhea-predominant irritable bowel syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000448-26 | Sponsor Protocol Number: ITOFD04-03 | Start Date*: 2005-01-05 |
Sponsor Name:Axcan Pharma Inc. (Axcan Pharma International BV is subsidiary of Axcan Pharma Inc.) | ||
Full Title: A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of Itopride HCl in patients suffering from functional dyspepsia | ||
Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024177-39 | Sponsor Protocol Number: RIBS-MIC/002/2010 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:ALFA WASSERMANN | |||||||||||||
Full Title: Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets. | |||||||||||||
Medical condition: Non constipation Irritable Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021367-32 | Sponsor Protocol Number: P07515 | Start Date*: 2010-08-20 |
Sponsor Name:Schering-Plough HealthCare Products, Inc | ||
Full Title: A Randomized, Open-Label, Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation | ||
Medical condition: Chronic constipation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001219-11 | Sponsor Protocol Number: PNCRLPCYS3001 | Start Date*: 2015-03-31 | |||||||||||
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development, L.L.C. | |||||||||||||
Full Title: A randomized double-blind (withdrawal) phase 3 study to evaluate the efficacy and tolerability of pancrelipase MT capsules compared with placebo in the treatment of subjects with cystic fibrosis-d... | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002748-10 | Sponsor Protocol Number: AD-02-013 | Start Date*: 2013-12-12 |
Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo | ||
Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreati... | ||
Medical condition: Patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005310-35 | Sponsor Protocol Number: AD-03-013 | Start Date*: 2014-08-13 |
Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo | ||
Full Title: A phase IV double-blind, randomized, placebo-controlled, multi-center study with pancreatic enzyme replacement therapy (PERT) in subjects suffering from pancreatic exocrine insufficiency (PEI) afte... | ||
Medical condition: Patients 2 weeks after discharge from the hospital after an attack of acute necrotizing pancreatitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003083-30 | Sponsor Protocol Number: PLAQHV | Start Date*: 2019-01-31 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects | |||||||||||||
Medical condition: The study is meant to have a better understanding in obesity and how we can prevent/cure it. Therefore, the product will first be tested in healthy, lean volunteers. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006118-17 | Sponsor Protocol Number: B3I105940 | Start Date*: 2006-08-17 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome | ||
Medical condition: Irritable Bowel Syndrome (IBS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005467-16 | Sponsor Protocol Number: 55995 | Start Date*: 2016-06-01 |
Sponsor Name:Maastricht University | ||
Full Title: Peppermint oil for the treatment of Irritable Bowel Syndrome: optimizing therapeutic strategies using targeted delivery | ||
Medical condition: Irritable Bowel Syndrome | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005026-31 | Sponsor Protocol Number: EFC6125 [AVE0005A/3001] | Start Date*: 2006-04-24 |
Sponsor Name:Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with ... | ||
Medical condition: pacientes con cáncer de ovario avanzado con ascitis maligna sintomática recurrente | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) GB (Completed) HU (Completed) AT (Prematurely Ended) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000308-16 | Sponsor Protocol Number: prucalopride1 | Start Date*: 2011-10-24 | ||||||||||||||||
Sponsor Name:UZ Leuven | ||||||||||||||||||
Full Title: Prucalopride versus Placebo in Idiopathic and Diabetic Gastroparesis | ||||||||||||||||||
Medical condition: Patients with delayed gastric emptying (t1/2 for solids ≥ 109 min) either from idiopathic or diabetic origin | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004561-41 | Sponsor Protocol Number: FGC-19-003 | Start Date*: 2020-03-20 | |||||||||||
Sponsor Name:The Functional Gut Clinic | |||||||||||||
Full Title: The use of Antacids and Alginates during Pre-Investigation Proton Pump Inhibitor Washout: Impact on Compliance and Symptom Burden | |||||||||||||
Medical condition: Gastro-oesophageal reflux disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000604-16 | Sponsor Protocol Number: ARD6772 | Start Date*: 2006-08-30 |
Sponsor Name:sanofi-aventis recherche & développement | ||
Full Title: A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites. | ||
Medical condition: Advanced ovarian cancer patients with recurrent symptomatic malignant ascites. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Completed) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
